ArticleMolecular pharmaceutics2025
Targeting Subcellular Organelles in Breast Cancer with Enzyme Induced Self-Assembly: Stimulated Response with Eyes-Absence Enzymes (EYA).
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.Journal of medicinal chemistry · 2026Article
- Dynamic pillar-perfusion platform for screening enzyme-induced self-assembling peptide therapeutics in 3D breast cancer spheroids.Bioengineering & translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Self-assembly of short peptides induced by enzymes is an emerging pathway to overcome drug resistance in cancer. However, specific targeting requires optimal precursor design and understanding of subcellular interactions. In our study, we synthesized six short peptides by modifying the N-terminal motif with fluorenylmethyloxycarbonyl (Fmoc), diphenyalanine (FF), arginylglycylaspartic acid (RGD), naphthyl (Nap), and 4-nitrobenz-2-oxa-1,3-diazole (NBD) motifs and including C terminal activation groups of tyrosine phosphate (pTyr) and threonine phosphate (pThr). We utilized the tyrosine phosphatase activity of Eye Absent Enzyme (EYA) to induce self-assembly of short peptides in breast cancer cells. The subcellular interaction of P1-P6 on DNA, mitochondria, and the cell membrane were evaluated in MDA-MB-231 (receptor-negative), MCF-7 (receptor-positive), and MCF10 (nontumorigenic epithelial breast) cells. Being dephosphorylated by EYA, the peptide transformed from monomers to assembled, which was confirmed by UV absorption shift and released phosphate. Studying protein expression showed that EYA2 is expressed in breast cancer cells but is absent in normal epithelial breast cells. The peptide/assemblies first aggregate on the cell membrane, then enter the cells, and accumulate in nuclei. Fmoc-FF-pTyr and RGD-FF-pTyr demonstrated significant binding affinity for phosphatidylserine on the surface of apoptotic cells. Among these, Fmoc-FF-pTyr effectively induced DNA damage and triggered apoptosis in cancer cells while remaining nontoxic to normal cells at optimal concentrations (10 μM). Peptides containing Nap groups selectively accumulated in the mitochondria of MCF-7 and MDA-MB-231 cells, enhancing the effectiveness of the doxorubicin treatments. These results demonstrate the critical role of EISA precursor in modulating phosphatase induced pathways by EYA's in breast cancer and the importance of considering these properties in nanotherapeutic design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.